Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Pharmacol.

Sec. Pharmacology of Anti-Cancer Drugs

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1673418

This article is part of the Research TopicNew Mechanisms for Anti-Cancer Drugs: Volume IIView all articles

Case Report: Fluzoparib Combined Exemestane in gBRCA2-mutated HR+/HER2− Advanced Breast Cancer

Provisionally accepted
Dunya  YangDunya YangXiaoyu  ZhangXiaoyu ZhangXinyu  HuXinyu HuShaoqin  LinShaoqin LinNaying  YuNaying YuXianglan  LinXianglan LinQunxiang  ChenQunxiang Chen*Xi  ChenXi Chen
  • Department of Oncology, The 900th Hospital of Joint Logistic Support Force, People’s Liberation Army (PLA), Fuzong Clinical College of Fujian Medical University, Fuzhou, China

The final, formatted version of the article will be published soon.

This case study details a 57-year-old woman with heavily pretreated, hormone receptor-positive (HR+), HER2-negative advanced breast cancer harboring a pathogenic germline BRCA2 mutation. Following progression on multiple prior therapies including endocrine therapy combined with a CDK4/6 inhibitor, chemotherapy, and an antibody-drug conjugate (resulting in liver metastases), blood-based next-generation sequencing (NGS) identified the gBRCA2 variant alongside persistent high ER expression. Guided by these molecular findings, treatment was initiated with the domestically developed, highly selective PARP inhibitor (PARPi) Fluzoparib (300 mg orally twice daily) combined with the aromatase inhibitor Exemestane (25 mg orally daily). The regimen was well-tolerated, with manageable grade 1-2 adverse events (anemia, nausea, rash). Follow-up imaging demonstrated complete resolution of the hepatic metastases. The patient achieved a remarkably prolonged progression-free survival (PFS) of 37 months on this combination therapy, representing the longest period of disease control in her metastatic course. Although eventual progression occurred (new axillary lymph node metastasis and suspected hepatic recurrence), this case demonstrates the exceptional efficacy and durable disease control achievable with Fluzoparib plus Exemestane in a pretreated patient with gBRCA2-mutated HR+/HER2-advanced breast cancer, highlighting a promising therapeutic approach for this molecularly defined population.

Keywords: Fluzoparib, BRCA, Mutation, breast cancer, PARP inhibitor, case report

Received: 25 Jul 2025; Accepted: 29 Sep 2025.

Copyright: © 2025 Yang, Zhang, Hu, Lin, Yu, Lin, Chen and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Qunxiang Chen, 554160863@qq.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.